Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
Zydus has in-licensed FYB206, a proposed biosimilar to immuno-oncology therapy Keytruda (pembrolizumab), exclusively from Formycon AG for the U.S. and Canadian markets
KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
